Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22877204 | 1.00 | POLB (0.40) | POLBGAAALDH1A1NPSR1NPC1 | |
| SCHEMBL26705039 | 0.94 | POLB (0.39) | POLBGAAALDH1A1NPSR1NPC1 | |
| SCHEMBL22877140 | 0.92 | POLB (0.41) | POLBGAAALDH1A1NPSR1NPC1 | |
| SCHEMBL22877195 | 0.91 | POLB (0.38) | POLBGAAALDH1A1NPSR1NPC1 | |
| SCHEMBL26429346 | 0.90 | CYP2D6 (0.39) | ALDH1A1CYP2D6SLC6A2SLC6A4LTB4R | |
| SCHEMBL26704684 | 0.90 | ALDH1A1 (0.39) | POLBGAAALDH1A1NPSR1CYP2D6 | |
| SCHEMBL26429627 | 0.89 | POLB (0.40) | POLBGAAALDH1A1NPSR1NPC1 | |
| SCHEMBL26429715 | 0.89 | POLB (0.40) | POLBGAAALDH1A1NPSR1NPC1 | |
| SCHEMBL22877159 | 0.89 | LTB4R (0.42) | POLBGAAALDH1A1LTB4RLTB4R2 | |
| SCHEMBL22877197 | 0.85 | GAA (0.38) | GAALTB4RLTB4R2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639340-B2 | Substituted chromanes, analogs thereof, and methods of use and synthesis | NORTHWESTERN UNIVERSITY (US) | 2023-05-02 | — | — | US | disclosed |
| US-20210009547-A1 | SUBSTITUTED CHROMANES, ANALOGS THEREOF, AND METHODS OF USE AND SYNTHESIS | NORTHWESTERN UNIVERSITY (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009547-A1 | SUBSTITUTED CHROMANES, ANALOGS THEREOF, AND METHODS OF USE AND SYNTHESIS | TYR, ME1, PNPO | POLB 1799/4885GAA 130/4885ALDH1A1 444/4885 |
| US-11639340-B2 | Substituted chromanes, analogs thereof, and methods of use and synthesis | TYR, ME1, PNPO | POLB 1799/4885GAA 130/4885ALDH1A1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.